Effect of slow-release theophylline on nasal antigen challenge in subjects with allergic rhinitis

European Respiratory Journal

Volumn 11, Issue 5, 1998, Pages 1105-1110

  Aubier, M ^a   Neukirch, C ^a   Maachi, M ^a   Boucara, D ^a   Engelstatter R ^b   Steinijans, V ^b   Samoyeau, R ^c   Dehoux, M ^a  

^a BICHAT HOSPITAL   (France)

^b ALTANA PHARMA AG   (Germany)

^c Laboratoires Byk France   (France)

Author keywords

Allergic rhinitis; ECP; Eosinophils; Inflammation; Theophylline

Indexed keywords

THEOPHYLLINE;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EOSINOPHIL; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MALE; NAUSEA; NOSE AIRFLOW; NOSE AIRWAY RESISTANCE; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PHARYNGITIS; POLYURIA; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SLOW RELEASE FORMULATION; THEOPHYLLINE BLOOD LEVEL; VOMITING;

ADULT; ANTIGENS; BLOOD PROTEINS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; IRRIGATION; LEUKOCYTE COUNT; MALE; NASAL CAVITY; NASAL PROVOCATION TESTS; RHINITIS, ALLERGIC, SEASONAL; RIBONUCLEASES; THEOPHYLLINE;

EID: 0031844387     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.11051105     Document Type: Article

References (32)

1. Smith JM. Epidemiology and natural history of asthma, allergic rhinitis and atopic dermatitis (eczema). In: Middleton E Jr, Reed CE, Ellis E, Adkinson NF Jr, Yungingh JW, eds. Allergy: Principles and Practice. Vol. 2. St. Louis, C.V. Mosby, 1988; pp. 891-929.
2. Pipkorn U, Karlsson G, Enerback L. The cellular response of the human allergic mucosa to natural allergen exposure. J Allergy Clin Immunol 1988; 82: 1046-1054.
3. Bascom R, Pipkorn U, Lichtenstein LM, Naclerio RM. The influx of inflammatory cells into nasal washings during the late response to antigen challenge: effect of systemic steroid treatment. Am Rev Respir Dis 1988; 138: 406-412.
4. Gleich G, Flavahan N, Fujisawa T, Vanhoutte PM. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol 1988; 81: 776-781.
5. 4 in allergic rhinitis. Allergy 1985; 40: 1-6.
6. Weller PF, Lee CW, Foster DW, Corey EJ, Austen KF, Lewis RA. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci USA 1983; 80: 7626-7630.
7. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? Eur Respir J 1994; 7: 579-591.
8. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-asthmatic effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343: 1006-1008.
9. Kidney J. Dominguez M,Taylor PM, Rose M, Chung KF, Barnes P. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151: 1907-1914.
10. Finnerty JP, Djukanovic R, Madden J, Holgate ST. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo controlled parallel group study. Eur Respir J 1996; 9: 1672-1677.
11. Venge P, Dahl R, Karlström R, Pedersen B, Peterson CGB. Eosinophil and neutrophil activity in asthma in a one-year double-blind trial with theophylline and two doses of budesonide. J Allergy Clin Immunol 1992; 89: 190.
12. Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 1995; 8: 637-642.
13. Naclerio RM, Bartenfelder D, Proud D. Theophylline reduces histamine release during pollen-induced rhinitis. J Allergy Clin Immunol 1986; 78: 874-876.
14. Aubier M; Levy J, Clerici C, Neukirch F, Cabrieres F, Herman D. Protective effect of theophylline on bronchial hyperresponsiveness in patients with allergic rhinitis. Am Rev Respir Dis 1991; 143: 346-350.
15. Bisgaard H, Gronborg H, Mygind N, Dahl R, Lindquist N, Venge P. Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: effect of the glucocorticoid budesonide. J Allergy Clin Immunol 1990; 85: 891-895.
16. Taylor G, Macneil AR, Freed DL. Assessing degree of nasal patency by measuring peak expiratory flow rate through the nose. J Allergy Clin Immunol 1973; 52: 193-198.
17. Dehoux MS, Boutten A, Ostinelli J, et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994; 150: 710-716.
18. Aubier M, Levy J. Clerici C, Neukirch F, Herman D. Different effects of nasal and bronchial glucocorticosteroid administration on bronchial hyperresponsiveness in patients with allergic rhinitis. Am Rev Respir Dis 1992; 146: 122-126.
19. Pipkorn U, Proud D, Lichtenstein LM, et al. Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest 1987; 80: 957-961.
20. Dutoit JL, Salmone CM, Woolcock AJ. Inhaled corticosteroids reduce the seventy of bronchial hyperresponsiveness in asthma but oral theophylline doses not. Am Rev Respir Dis 1987; 138: 1174-1178.
21. Pastorello EA, Riario-Storza GG, Incorvaia C, Segala M, Fumagalli M, Gandini R. Comparison of rhinomanometry, symptoms score, and inflammatory cell counts in assessing the nasal late-phase reaction to allergen challenge. J Allergy Clin Immunol 1994; 93: 85-92.
22. Aubier M, Barnes PJ. Theophylline and phosphodiesterase inhibitors. Eur Reapir J 1995; 8: 347-348.
23. Gozzard N, Hend CM, Blake SM, et al. Effects of theophylline and solipram an antigen-induced airway responses in nesnatally rabbits. Br J Pharmacol 1996; 117: 1405-1412.
24. Hatzelmann A, Tenor H, Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol 1995; 114: 821-831.
25. Schudt C, Tenor H, Hatzelmann A. PDE isoenzymes as targets for antiasthmatic drugs. Eur Respir J 1995; 8: 1179-1183.
26. Ohta K, Sawamoto S, Nakajima M, Nagai A, Tanaka Y, Hirai K. Theophylline induces apoptosis in eosinophils surviving with interleukin-5 in vitro. J Allergy Clin Immunol 1994; 93: 200-206.
27. Bradding P, Feather IH, Wilson S, et al. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. Journal of Immunology 1993; 151: 3853-3865.
28. Lopez AF, Sanderson CJ, Gamble JR, Campbell HR, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167: 219-225.
29. Mascali JJ, Cuietusa P, Negri J, Borish L. Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann Allergy Asthma Immunol 1996; 77: 34-38.
30. Pretolani M, Goldman M. IL-10: a potential therapy for allergic inflammation? Immunology Today 1997; 18: 227-280.
31. Marshall JS, Leal-Berumen I, Nielsen L, Glibetic M, Jordana M. Interleukin IL-10 inhibits long-term 1L-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest 1996; 97: 1122-1128.
32. Lozewicz S, Wang J, Duddle J. et al. Topical glucocorticoids inhibit activation by allergen in the upper respiratory tract. J Allergy Clin Immunol 1992; 89: 951-957.